Clinical Trials Logo

Citation(s)

Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer

Details for clinical trial NCT01229150